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Tumor growthEwing's sarcoma (ES) is a primary bone tumor characterized by a chromosomic translocation between the EWS
gene and amember of the ETS gene family, mainly FLI1, which leads to an aberrant transcription factor EWS–FLI1
that promotes tumorigenicity. Gap junctions are intercellular channels composed of transmembrane proteins
(connexin: Cx), that allow direct intercellular communication between adjacent cells. Numerous studies have
shown that tumorigenesis may be associated with a loss of gap junctional intercellular communication (GJIC).
Loss of Cx43 expression was observed at the protein and mRNA levels in ES cell lines compared to those mea-
sured in human mesenchymal stem cells. A673 ES cells stably transfected with an shRNA targeting EWS–FLI1
showed an increase in Cx43 expression (at the mRNA, protein and transcriptional levels) and GJIC. In an
osteolyticmurinemodel of ES, the overexpression of Cx43 in ES cells dramatically reduced tumor growth, leading
to a signiﬁcant increase in animal survival. In vitro assays showed that Cx43 overexpression increases the p27
level with an associated marked decrease of Rb phosphorylation, consistent with the observed blockade of the
cell cycle in G0/G1 phase. In addition, the bone microarchitectural parameters, assessed by micro-CT analysis,
showed an increased bone volume when Cx43 expression was enhanced. Histological analysis demonstrated
that the overexpression of Cx43 in ES tumor cells inhibits osteoclast activity and therefore bone resorption.
Our study demonstrated that the loss of Cx43 expression in ES cells plays a crucial role in the development of
the primary tumor and the associated bone osteolysis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ewing's sarcoma (ES) is the second most frequent pediatric bone
cancer after osteosarcoma. It is a rare, aggressive, poorly differentiated
tumor of bone and soft tissue which occurs primarily in children, ado-
lescents and young adults [1–3]. ES is characterized by a rapid prolif-
eration of tumor cells with small round nuclei that causes extensive
and rapidly progressive bone destruction [4]. ES is a classic example
of a malignancy driven by a fusion oncogene, 85% of ES tumor speci-
mens harboring the t(11;22)(q24;q12) chromosomal rearrangement
[5]. The resultant fusion transcript EWS–FLI1 is formed by the09010NN-REGIONPDL); Ligue
Médecine, 1 rue Gaston Veil,
3 240412860.
ecchia).
rights reserved.N-terminal part of the EWS protein linking to the DNA-binding do-
main (ETS domain) of the FLI1 transcription factor [6]. FLI1 possesses
carcinogenic properties of cell cycle induction, aberrant transcription
and promotion of cell survival when associatedwith EWS [7]. Alterna-
tive rarer translocations are known such as, EWS/ERG occurs in
approximately 10% of cases, EWS/ETV, EWS/EIAF and EWS/FEV each
in b1% of cases. Although the cell origin of ES remains unknown,
there is a growing body of evidence that suggests ES is derived from
humanmesenchymal stem cells (hMSC). Indeed, strong arguments in-
dicate that the fusion gene EWS-FLI1 may induce the transformation
of hMSC into ES cells [8].
Connexins, the structural proteins of gap junctions, are a family
of transmembrane proteins that oligomerize into hemichannels
containing six connexin subunits [9]. Upon reaching the cell surface,
two hemichannels pair to complete an intercellular gap junction chan-
nel, which directly links the cytoplasm of neighboring cells andmediate
the exchange of low-molecular-mass molecules (b1000 Da), including
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junctions isﬁnely regulated at the transcriptional [11,12] and posttrans-
lational level via cycles of connexin phosphorylation [13], intracellular
Ca2+ or H+ concentrations [14,15] (for reviews, see Refs. [16–18]). A
critical role in the progression of a variety of tumors has been attributed
to gap junction intercellular communication (GJIC) [19,20]. Reduced or
loss of gap junctional activity through different mechanisms including
reduced expression has been implicated in various human cancers
[21]. The crucial role of altered GJIC in tumor progression was further
demonstrated by the exogenous expression of connexins in gap
junction-deﬁcient cell lines, which was shown to restore functional
communication and to delay tumor growth [22,23]. The number of pos-
sible mechanisms responsible for connexin-mediated tumor suppres-
sion has grown with insights into the possible functional roles of
hemichannels [24], cross-talk between gap junctions and other
adhesion-based junctional complexes [25] and the discovery of novel
connexin-binding proteins [26]. Thus, increasing evidence suggests
that GJ-independent mechanisms are also involved in connexin-
mediated tumor suppression [20,21].
Despite many studies having demonstrated the importance of
connexin43 (Cx43), the most abundant connexin in bone cells, for bone
development and turnover during the last decade [27], little is currently
known about GJIC and Cx43 in primary bone tumors. In this report,
we analyzed the speciﬁc role of Cx43-driven GJIC in ES tumor growth.
Using a combination of in vitro and in vivo experimental approaches,
we demonstrated: i) a lack of Cx43 gene expression in ES cells, ii) that
the expression level of Cx43 is associated with that of EWS–FLI1,
iii) that Cx43 inhibits ES tumor growth via modulation of cell prolifera-
tion, and iv) Cx43 reduces tumor cell-driven osteoclast activity.
2. Materials and methods
2.1. Cell cultures
Human ES cells were cultured in DMEM (Dulbecco's Modiﬁed
Eagle's Medium, Lonza, Basel, Switzerland) or RPMI (Roswell Park
Memorial Institute, Lonza) supplemented with 10% fetal bovine
serum (FBS; Hyclone Perbio, Bezons, France). A673 ES cells stably
transfected with an inducible shRNA against EWS–FLI1 were treated
with doxycycline (1 μg/ml) to induce shRNA expression (A673-1c
cells) [8]. Bone marrow, harvested by iliac crest aspiration from
donors (age=46±12; range=36–67), were obtained from the
“Etablissement Français du Sang” with informed consent and ethical
approval from the Nantes University Hospital Ethics Committee.
hMSCs were cultured in DMEM, 10% FBS, 1 ng/ml basic ﬁbroblast
growth factor (R&D systems, Lille, France). Adherent cells were char-
acterized by ﬂow cytometry (CD45−, CD34−, CD105+, CD73+and
CD90+, purity≥99%) prior to further experiments.
All in vitro experiments were made with identical number of cells
at the same density.
2.2. Western blot analysis
Cellswere lysed in a lysis buffer (SDS 1%, Tris pH 7.4 10 mM, sodium
orthovanadate 1 mM) and protein concentration was determined by
BCA kit (Sigma, St Quentin-Fallavier, France). 10 μg of total protein
extracts in Laemmli buffer (62.5 mM Tris–HCl, pH 6.8, 2% SDS, 10%
glycerol, 5% 2-mercaptoethanol, 0.001% bromophenol blue) were sepa-
rated by SDS-polyacrylamide gel electrophoresis, and transferred to
Immobilon-P membranes (Millipore, Billerica, MA, USA). Membranes
were immunoblotted with mouse monoclonal anti-Connexin43 (dilu-
tion 1/1000, Sigma), rabbit polyclonal anti-Fli1 (dilution 1/1000,
Santa Cruz Biotechnology, CA, USA), mouse monoclonal anti-GAPDH
(dilution 1/2000, Abcam, Paris, France), or rabbit polyclonal anti-β-
actin (dilution 1/10,000, Sigma) antibodies. Antibody binding was
visualized with the enhanced chemiluminescence system (SuperSignalWest Pico Chemiluminescent Substrate, ThermoSientiﬁc, Illkirch,
France). For quantiﬁcation, luminescence was detected with a Charge
Couple Device (CCD) camera and analyzed using the GeneTools pro-
gram (Syngene, Cambridge, United Kingdom). To speciﬁcally evaluate
the phosphorylation status of Cx43, cells were lysed in RIPA buffer
(10 mM Tris pH8, 1 mM EDTA, 150 mM NaCl, 1% NP40, 0.1% SDS)
containing a cocktail of protease and phosphatase inhibitors (1 mM
sodium orthovanadate (Na2VO4), 1 mM phenylmethylsulforyl ﬂuoride
(PMSF), 10 mM sodium ﬂuoride (NaF), 10 mM N-ethylmaleimide
(NEM), 2 μg/ml leupeptin and 1 μg/ml pepstatine) at 4 °C and were
sonicated twice for 30 s. 50 μg of total protein were then separated by
SDS-polyacrylamide gel electrophoresis.
2.3. Cx43 immunostaining
Cells were cultured in plastic chamber microscope slides (Millicell
EZ Slide, Millipore, Billerica, MA, USA), ﬁxed in 4% paraformaldehyde
for 10 min at room temperature, and permeabilized in 0.5% saponin/
PBS. Cells were incubated with a primary antibody (mouse monoclo-
nal anti-Cx43, Sigma) at a 1:100 dilution for 2 h at room temperature
and a secondary antibody (Alexa Fluor 647 nm goat anti-mouse IgG,
Invitrogen, Carlsbad, CA, USA) at a 1:500 dilution for 1 h at room
temperature. Slides were mounted with liquid Prolong Gold antifade
reagent with Dapi (Molecular Probes) and observed under a confocal
microscope (Nikon A1Rs 60× NA 1.4). All controls performed by
omitting the primary antibody were negative.
2.4. Cell cycle analysis
Cells were incubated in serum-free medium during 12 h and then
in medium supplemented with 10% serum. Cell cycle distribution
was studied by ﬂow cytometry (Cytomics FC500; Beckman Coulter,
Villepinte, France) based on 2 N and 4 N DNA content (50 μg/ml
propidium iodide) and analyzed by using DNA Cell Cycle Analysis
Software (Phoenix FlowSystems, San Diego, CA, USA).
2.5. Real-time polymerase chain reaction
Total RNAwas extracted using NucleoSpin®RNAII (Macherey Nagel,
Duren, Germany). 1 μg of total RNA was used for ﬁrst strand cDNA
synthesis using ThermoScript RT-PCR System (Invitrogen). DNase I
treatment (25 units, 15 min) of total RNA was performed to eliminate
genomic contamination. Real-time PCRwas performedwith a Chromo4
instrument (Biorad, Richmond, CA, USA) using SYBR Green Supermix
reagents (Biorad). Primer sequences are provided in Supplementary
Table 1. Calibration curves with different amounts of cDNA were used
to validate the primers according the MIQE guidelines [28].
2.6. Transient cell transfections, reporter assays and plasmid constructs
Transient cell transfections were performed with jetPEI™
(Polyplus-transfection, Illkirch, France). The phRLMLP-Renilla lucifer-
ase expression vector was cotransfected in every experiment to mon-
itor transfection efﬁciencies. Luciferase activity was determined with
the Dual-Luciferase reporter assay system (Promega, Charbonnieres,
France). The Cx43 promoter/gene reporter construct−2400Cx43-lux
has been described previously [29]. The expression vector of the
Cx43 gene was generated by PCR using the Cx43-EGFP plasmid [30]
as template and cloned inpcDNA3.1 vector.
2.7. Parachute assay
GJIC was determined by parachute assay, as previously described
[31,32]. This method utilizes ﬂuorescence-activated cell sorting
(FACS) analysis to study intercellular dye transfer. Brieﬂy, cell cul-
tures were divided into “acceptor” and “donor” cell groups. Adherent
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membrane dye for 1 h, and conﬂuent donor cells were dyed with
calcein-acetoxymethylester (calcein-AM; Sigma) for 45 min. After
loading, cells were washed in PBS to remove the excess dye. Then,
the calcein-AM-dyed cells were trypsinized and parachuted on the
DiI-dyed acceptor cell layer at a cell ratio of 1/10 and incubated for
2 h at 37 °C to allow dye transfer via gap junctions. Dye coupling
was analyzed using ﬂow cytometry conducted with a FACS FC500
cytometer. For the analysis of results, gates were established on
the day of each experiment using non-dyed cells, cells dyed with
calcein-AM, and cells dyed with DiI. The quantiﬁcation of dye transfer
is explained in more detail in Supplementary Figure S1 legend.
2.8. Ewing's sarcoma model
Four-week-old female Rj:NMRI-nude mice (Elevages Janvier, Le
Genest Saint Isle, France) were maintained under pathogen-free
conditions at the Experimental Therapy Unit (Faculty of Medicine,
Nantes, France) in accordance with the institutional guidelines
of the French Ethical Committee (CEEA Pays de la Loire no.06;
CEEA-2010-23) and under the supervision of authorized investiga-
tors. The mice were anesthetized by inhalation of an isoﬂurane/air
mixture (1.5%, 1 L/min) before receiving an intramuscular injection
of 2·106 TC71 or A673 cells in close proximity to the tibia, leading
to a rapidly growing tumor in soft tissue with secondary contiguous
bone invasion. Tumors appeared at the injection site 8 days later.
The tumor volume (V) was calculated from the measurement of two
perpendicular diameters using a caliper, according to the following
formula: V=0.5×L×(S)2, in which L and S are, respectively, the
largest and smallest perpendicular tumor diameters as previously de-
scribed [33]. Mice were sacriﬁced when the tumor volume reached
3000 mm3 for ethical reasons.
2.9. Micro-CT analysis
Analyses of bone microarchitecture were performed using the
high-resolution X-ray micro-CT system for small-animal imaging
SkyScan-1072 (SkyScan, Kartuizersweg, Belgium). Analyses were
performed both on live and anesthetized animals [xylazine (Rompun®;
Bayer)-ketamine (Imalgène®1000; Merial) 8% and 13%, respectively, in
PBS; 100 μl/10 g], at different tumor volumes (500 and 1000 mm3),
and at necropsy (3000 mm3). All tibiae/ﬁbulae were scanned using
the same parameters (pixel size 18 μm, 50 kV, 0.5-mm Al ﬁlter and
0.8° of rotation step). Three-dimensional reconstructions and analysis
of bone parameters were performed using CTvol and CTan software
(Skyscan).
2.10. Bone histology
After sacriﬁce, the tibiae were conserved and ﬁxed in 10% buffered
formaldehyde, decalciﬁed (4% EDTA, 0.2% paraformaldehyde, pH 7.4),
and embedded in parafﬁn. 3-μm sections of tumor-bearing tibiae
were cut and stained for tartrate-resistant acid phosphatase (TRAP)
to analyze osteoclast activity. Quantiﬁcation of osteoclastic areas
was done using ImageJ (National Institutes of Health, USA).
2.11. Immunohistochemistry
3-μm sections of tumor tissues (embedded in parafﬁn) were cut
and stained for Ki-67, active caspase 3 and osterix, respectively,
with monoclonal mouse anti-human Ki-67 (Dako, Trappes, France),
rabbit polyclonal anti-active Caspase 3 (Abcam) or rabbit polyclonal
anti-osterix (Abcam) antibodies. Immunodetection was performed
using DAB Substrate-Chromogen (Dako) and counterstained with
hematoxylin.2.12. Statistical analysis
All analyses were performed using GraphPad Prism 4.0 software
(GraphPad Software, La Jolla, CA, USA). In vitro experiments results
were analyzed with the unpaired t-test and are given as mean±SD.
For in vivo experiments, results from groups overexpressing Cx43
were compared with control groups (Parental and Mock) using
the ANOVA test followed by Dunnett's multiple comparison test and
are given as mean±SEM. Results with pb0.05 were considered
signiﬁcant.
3. Results
3.1. Loss of Cx43 gene expression in ES cells
To evaluate the Cx43 production in ES cells, Western-blot analysis
was performed to compare Cx43 protein levels in seven ES cell lines
with those measured in hMSC from ﬁve healthy donors. As shown
in Fig. 1A, Cx43 protein levels were dramatically reduced in all tested
ES cell lines (by approximately 80%) with regard to the mean level
measured in hMSC. To determine whether this decrease occurred
via modulation of the corresponding gene, Cx43 mRNA steady-state
levels were measured by qRT-PCR. As shown in Fig. 1B, the Cx43
mRNA levels are dramatically reduced in ES cells. By contrast, the
expression of Cx45, a connexin expressed by both hMSC and ES
cells, was not signiﬁcantly different in hMSC and ES cells (Fig. 1C).
The Cx43 localization was then examined by immunostaining
(Fig. 1D). As previously described [34], Cx43 is expressed predomi-
nantly along regions of intimate cell-to-cell contact and also within
regions of the cytoplasm in hMSC cells. In the region of intercellular
contact, Cx43 has a high punctate distribution which is characteristic
for GJ channels. In ES cells, such as RDES (Fig. 1D) or A673, TC32,
EW24 and TC71 (not shown) cells, Cx43 expression is observed
along regions of intimate cell-to-cell contact. A low expression of
Cx43 is also observed within the cytoplasm in ES cells indicating
that the localization of Cx43 is not fundamentally different between
hMSC and ES cells.
To determine whether loss of Cx43 gene expression is associated
with gap junctional intercellular communication changes, GJIC was
quantiﬁed by FACS analysis using the parachute assay. As shown in
Fig. 1E, a strong decrease (approximately 70%) of the transfer-ratio
was measured in A673 ES cells compared to hMSCs cells, indicating
that the loss of Cx43 gene expression in A673 cells is associated with
a decrease in the ability of these cells to form functional channels. Sim-
ilar results were obtained using other ES cells such as TC71, EW24,
RDES and TC32 cells (not shown).
To exclude the hypothesis that a defect of Cx43 phosphorylation
could explain the decrease in GJIC observed in ES cells, a Western-blot
analysis under appropriate conditions was performed. As shown in
Fig. 1F, the phosphorylated forms of Cx43 (P1 and P2 bands) were
detected in both, hMSC and ES cells.
Together these results demonstrate that the decrease of GJIC in ES
cells is mainly due to the loss of Cx43 expression rather than to a de-
fect of Cx43 localization and/or phosphorylation.
3.2. EWS–FLI1 represses Cx43 gene expression
Given the crucial role played by EWS–FLI1 in ES tumor growth, we
hypothesized that EWS–FLI1 may regulate Cx43 gene expression. To
test this theory, A673 ES cells stably transfected with an inducible
shRNA targeting EWS–FLI1 were treated with doxycycline to induce
shRNA expression (A673-1c cells) [8]. As expected, the presence
of doxycycline induced a decrease in EWS–FLI1 protein levels in a
time-dependent manner (Fig. 2A). Interestingly, when EWS–FLI1 pro-
duction was decreased, this caused a subsequent increase in Cx43
protein levels (Fig. 2A). A673-1c cells exhibited a 7-fold higher
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Fig. 1. Loss of Cx43 gene expression in ES cell lines (A) Cx43 production was detected byWestern blot analysis of whole cell lysates of hMSC from ﬁve healthy donors and seven ES cell lines
(upper panel). Speciﬁcity of the modulation was conﬁrmed with an anti-GAPDH antibody (middle panel). The ratio of Cx43 to GAPDH is plotted from the values of one representative exper-
iment of three experiments (lowerpanel). (B)Cx43mRNAsteady-state levels inhMSCandES cell linesweredeterminedbyqRT-PCR. Bars indicatemean±SDof three independent experiments
performed, each with duplicate samples. (C) Cx45mRNA steady-state levels in hMSC and ES cells were determined by qRT-PCR. Bars indicate mean±SD of three independent experiments
performed in duplicate. (D) Cultures of hMSC and ES cellswereﬁxed, permeabilized and stainedwith amonoclonal antibody directed against Cx43 as detected by indirect immunoﬂuorescence.
Cx43 immunolocalization (red) and counterstaining of nuclei (dapi, blue) showhigh immunostaining at cell–cell boundaries (arrows) and aweak immunostainingwithin the cytoplasmboth in
hMSC and ES cells. Images represent one representative experiment of three experiments. (E) FACS analysis of parachute studies in hMSC and A673 ES cells. Histograms indicate mean±SD of
the relative transfer-ratio of calcein between cellsmeasured in three independent experiments performed in duplicate (*pb0.05). (F) Phosphorylation status of Cx43was evaluated byWestern
blot analysis of whole cell lysates of hMSC and ES cells (upper panel, P1 and P2 bands). Speciﬁcity of the modulation was conﬁrmed with an anti-GAPDH antibody (lower panel).
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557J. Talbot et al. / Biochimica et Biophysica Acta 1832 (2013) 553–564production of Cx43 8 days after addition of doxycycline. To determine
whether this increase in Cx43 protein production occurred via modu-
lation of the corresponding gene, Cx43mRNA steady-state levels were
measured by qRT-PCR. As shown in Fig. 2B, Cx43 expression was in-
duced under doxycycline treatment. At day 2, 4 and 8 after addition
of doxycycline, A673-1c cells respectively exhibited 2-, 6- and
10-fold higher Cx43 mRNA steady state levels. To determine whether
this effect of EWS–FLI1 on Cx43 gene expression takes place at the
transcriptional level, transient cell transfections were performedwith the Cx43 promoter/gene reporter construct −2400Cx43-lux.
Doxycycline stimulation induced a 38-fold transactivation of the
Cx43 promoter (Fig. 2C). To determine whether the increase of
Cx43 gene expression in A673-1c under doxycycline stimulation
is associated with gap junctional intercellular communication
changes, GJIC was quantiﬁed by FACS analysis using the parachute
assay. Doxycycline-induced Cx43 protein expression (Fig. 2A)
signiﬁcantly enhanced GJIC 8 days after addition of doxycycline
(Fig. 2D).
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558 J. Talbot et al. / Biochimica et Biophysica Acta 1832 (2013) 553–564Finally, Cx43 localization was examined by immunostaining. As
shown in Fig. 2E (left panel) Cx43 is expressed predominantly
along regions of intimate cell-to-cell contact and weakly within re-
gions of the cytoplasm in absence of doxycycline. As illustrated in
Fig. 2E (right panel), 8 days after treatment with doxycycline the in-
crease in Cx43 expression measured using Western blot analysis
(Fig. 2A) was both detected in the region of intercellular contact
(Fig. 2E arrows) and within the cytoplasm (Fig. 2E asterisk). We
can speculate that the low increase of GJIC (1.7 fold, Fig. 2D) under
doxycycline treatment compared with the high increase in protein
production (7-fold, Fig 2A) was mainly due to the fact that Cx43
expressed within the cytoplasm does not form functional intercellular
channels.
Together, these results demonstrated that EWS–FLI1 represses
Cx43 gene expression and also the cell–cell communication between
ES cells.P M Cx43 P M Cx43
C
0
1
2
3
4
5
R
el
at
iv
e 
tra
ns
fe
r-r
at
io
0
1
2
3
4
5
R
el
at
iv
e 
tra
ns
fe
r-r
at
io
P M Cx43 P M Cx43
Fig. 3. Overexpression of Cx43 in TC71 andA673 ES cell lines. (A) Cx43mRNA steady-state
levels in TC71 or A673 ES cells (parental (P), mock- (M), Cx43-transfected (Cx43)) were
determined by quantitative RT-PCR. (B) Cx43 production in TC71 and A673 ES cell
were determined by Western blot. (C) FACS analysis of parachute studies in TC71 and
A673 ES cells. Histograms indicate mean±SD of the relative transfer-ratio of calcein be-
tween cells measured in three independent experiments performed, each with duplicate
samples.3.3. Overexpression of Cx43 in TC71 and A673 ES cell lines dramatically
inhibits in vivo tumor growth
Since a reduced GJIC activity has been implicated in the develop-
ment of various human cancers, we hypothesized that the decrease
of Cx43 gene expression observed in ES cells plays a role in ES
tumor growth. Since we observed a loss of Cx43 gene expression in
ES cells, a gain of function approach instead of a loss of function was
used to test this hypothesis.
We stably transfected twohuman ES cell lines (TC71 andA673)with
Cx43 cDNA to examine this issue. Clones were generated, selected
and analyzed in comparison with parental cell lines (P) and mock-
transfected cells (M) for their Cx43 expression. To avoid the phenotypic
artifacts that may result from the selection and propagation of indi-
vidual clones derived from single transfected cells, a cell pool was
generated. This pool, composed of cells from ﬁfteen positive clones,
was analyzed in comparison with parental cells and a pool of mock-
transfected cells for their Cx43 mRNA and protein levels. Both Cx43–
TC71 and Cx43–A673 cells expressed signiﬁcantly higher levels of
Cx43 mRNA (Fig. 3A) and protein (Fig. 3B) compared to parental and
mock-transfected cells. Of note, the expression level of Cx45 is not
modiﬁed after overexpression of Cx43 (not shown). In addition, we
examined whether increased Cx43 expression in TC71 and A673 cells
may affect their GJIC. In contrast to the low transfer-ratio measured
in parental and mock-transfected cells, a signiﬁcant increase in GJIC
was observed in Cx43 overexpressing cells indicating that these cells
were coupled forming interconnecting networks where they were
able to communicate (Fig. 3C).
Next, a preclinical experimental model of ES induced by paratibial
injection of either TC71 (Fig. 4) or A673 (Supplementary Fig. S2) ES
cells was developed. Cx43 overexpression dramatically inhibited
tumor growth in both TC71 and A673 injected mice (Fig. 4 and
Supplementary Fig. S2). While 100% of mice injected with parental
TC71 and 87.5% of mice receiving mock-transfected cells developed
tumor volumes of ≥1000 mm3 17 days after injection, only 25% of
mice injected with Cx43-transfected cells developed a tumor volume
of ≥1000 mm3 (Fig. 4A). The mean tumor sizes at day 17 were re-
spectively 2384±293 mm3 and 2219±331 mm3 in mice injected
with parental and mock-transfected TC71 cells, whereas the mean
tumor size in mice injected with the Cx43-transfected cells was
995±233 mm3 (mean±SEM, pb0.001; Fig. 4B). Similar results
were obtained in the A673 experimental model (Supplementary
Fig. S2). The reduced mean tumor sizes indicated that Cx43 over-
expression slowed tumor growth in both, the TC71 and A673 model
by 55% (pb0.05) compared with control mice. Consequently, Cx43
overexpression increased animal survival by 70% (pb0.05) and 50%
(pb0.01), respectively, in the TC71 (Fig. 4C) and A673 (Supplementary
Fig. S2C) model compared with control animals.Tumors excised from sacriﬁced animals were then assessed
for proliferation and apoptosis by immunohistochemical staining for
Ki-67 and caspase-3, respectively. Staining for Ki-67 positive cells re-
vealed that Cx43 overexpression resulted in a signiﬁcant inhibition
of cell proliferation in both ES experimental models (Fig. 5A), which
is consistent with the smaller size of the Cx43 tumors. The mean
number of Ki-67 positive cells counted by microscopy (×20) in six
random ﬁelds was 31±0.8 and 33±1.8, respectively, in tumors
from mice injected with parental and mock-transfected TC71 cells,
whereas this number was 20±1.4 in Cx43-expressing tumors
(***pb0.01; Fig. 5A). Contrarily, staining for caspase-3 positive cells
revealed no signiﬁcant differences between the groups (data not
shown) suggesting that the effect of Cx43 tumor growth is mainly
due to inhibition of tumor cell proliferation rather than induction
of tumor cell death.
To understand the mechanisms underlying the effect of Cx43 on
cell proliferation, we carried out several in vitro experiments. First,
a cell growth curve assay demonstrated that Cx43-transfected TC71
or A673 cells display a reduced proliferation rate (50% lower at
day 7) compared to parental or mock-transfected cells (***pb0.01;
Fig. 5B). Next, we performed ﬂow cytometry of parental, mock- and
Cx43-transfected TC71 and A673 cells to assess DNA content after
24 h of culture growth. Cx43 overexpression resulted in cell cycle
arrest in G0/G1 phase (Fig. 5C), as demonstrated by a 50% increase
in the number of cells in G0/G1 phase in Cx43-transfected cells
compared with parental or mock-transfected cells in TC71 ES cells.
Western blot analysis was then used to examine which DNA check
points in cells were involved in mediating cell cycle arrest. As
shown in Fig. 5D, Cx43 overexpression increased p27 levels with an
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the observed blockade of the cell cycle in G0/G1 phase. Similar results
were obtained with A673 model (Fig. 5D).
Together these results demonstrated that Cx43 regulates Ewing's
tumor growth via modulation of cell proliferation.
3.4. Overexpression of Cx43 in TC71 and A673 ES cells inhibits bone
resorption
Since ES altered bone remodeling plays a central role in the devel-
opment and progression of ES bone tumors, we evaluated the ability
of Cx43 to alter tumor-induced bone resorption. To this aim, the
microarchitecture of bone was examined after animal sacriﬁce using
a high-resolution X-raymicro-CT system. Analysis of the tibiae/ﬁbulae
suggests that Cx43 overexpression decreased tumor-induced bone
osteolysis in A673 ES model and favors the bone formation in TC71
ES model. To conﬁrm this observation, the bone volumes were mea-
sured after three-dimensional reconstruction (Fig. 6A and B). The
mean of bone volumes were 12.5±0.6 mm3 and 12.7±0.5 mm3
in mice injected with parental or mock-transfected TC71 cells,respectively, whereas the mean bone volume in mice carrying Cx43–
TC71 tumors was 15±0.3 mm3 (mean±SEM;***pb0.01; Fig. 6A).
Similarly, Cx43 enhanced bone volume in mice injected with A673
cells (**pb0.05; Fig. 6B). To fully evaluate the ability of Cx43 to in-
crease bone volume, these measures were compared for equivalent
tumor volumes at, respectively, 500, 1000 and 3000 mm3. At a
tumor volume of 3000 mm3, the mean bone volume was 13.3±
0.6 mm3 inmice injectedwithmock-transfected TC71 cells, compared
to 16.4±0.5 mm3 in mice injected with Cx43-transfected cells
(mean±SEM;***pb0.01; Fig. 6C). Furthermore, while bone volumes
of control mice remained constant (around 13 mm3), the bone
volumes of mice injected with Cx43-transfected TC71 cells gradually
increased with tumor size (from 14.4±0.7 mm3 to 16.4±0.5 mm3
when tumor volumes increased from 500 to 3000 mm3, Fig. 6C).
Similar results were obtained with mice injected with A673 ES cells
(Supplementary Fig. S3).
To understand the mechanisms underlying the effect of Cx43 on
tumor-induced bone formation, the activity of osteoclasts and osteo-
blasts, two cell lineages implicated in bone remodeling, was assessed.
Tartrate resistant acid phosphatase (TRAP) staining in sections of
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the number and size of TRAP+multinucleated cells, both in growth
plate (Fig. 7A) and at the interface bone-tumor (Fig. 7B), relative
to the control conditions. By contrast, osterix immunostaining ofthe same samples showed no signiﬁcant difference between mice
injected with Cx43-transfected cells and animals receiving parental
or mock-transfected cells (Fig. 7C). Similar results were obtained in
the A673 model (data not shown).
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formation may be due to inhibition of osteoclast activity rather than
to a stimulation of osteoblast activity.
4. Discussion
Observations indicating a role of connexin in tumorigenesis
are supported by many in vitro analyses demonstrating the down-
regulation or loss of connexin expression in a wide range of neoplas-
tic cells and primary tumors [35–37]. Here, we demonstrated a loss of
Cx43 gene expression in ES cell lines. Early works using the NIH3T3
cell model have demonstrated that EWS–FLI1 acts as a transcriptional
activator that allows oncogenic transformation [38,39]. Current
opinion holds that EWS–FLI1 functions as an aberrant transcription
factor supported by works which demonstrated that EWS–FLI1 local-
izes to the nucleus, binds DNA in a site-speciﬁc manner and possesses
a powerful transcriptional activator that is more potent than the na-
tive FLI1 [7]. Gene expression studies have further demonstrated
that EWS–FLI1 is able to enhance the expression of many genes impli-
cated in transformation and/or tumor progression, including MYC
[40], ID2 [41], CCND1 [42] and PDGFC [43]. Other studies have re-
vealed that EWS–FLI1 is able to decrease the expression of many
genes including those encoding p21 [44], p57kip [45], TGFβRII [46]
and IGFBP3 [47]. Among these, only the TGFβRII and IGFBP3 genes,
which are down-regulated by EWS–FLI1, have been identiﬁed as
direct EWS–FLI1 targets [48]. Here, using a EWS–FLI1 knock-down
approach, we demonstrated that EWS–FLI1 affects the Cx43 gene
expression, suggesting that Cx43 is a EWS–FLI1 target gene. However,
we cannot exclude that Cx43 induction in response to EWS–FLI1
silencing is a consequence of modiﬁed cell differentiation for exam-
ple. The exact mechanisms underlying the down-regulation of Cx43
gene by EWS–FLI1 remain to be elucidated.Through a molecular gain-of-function approach, we demonstrated
that Cx43 overexpression inhibits in vivo ES tumor growth, providing
the ﬁrst experimental evidence indicating that the decrease of Cx43
gene expression is one mechanism through which ES cells can acquire
high tumor growth potential. Since the main function of connexins is
the formation of intercellular channels, the mechanisms by which
connexins modulate cell proliferation and thus tumor growth were
ﬁrstly proposed to depend on the ability of these channels to promote
exchange of molecules that regulate the cell cycle [49]. Over the past
40 years, numerous studies have demonstrated a loss or at least a de-
crease of GJIC between cancer cells or between cancer cells and their
surrounding normal cells, supporting the link between gap junction
defects and tumor growth [20]. In agreement with this dogma, nu-
merous studies reported that many tumor promoters were indeed
inhibitors of GJIC [50] supporting the idea that the inhibition of GJIC
during the tumor promoting stage may favor the clonal expansion
of initiated cells [20,51]. It was thus proposed that the recovery of
GJIC between cancer cells could inhibit their proliferation and by
consequence in vivo tumor growth. In this context, over-expression
of connexins in different tumor cells was shown to restore GJIC and
therefore inhibit cell proliferation [20,21,35]. Although we showed
that Cx43 overexpression in ES cells restores GJIC, we cannot exclude
that the effect of Cx43 overexpression on cell proliferation and in vivo
tumor growth was not associated with the restoration of GJIC. Indeed,
numerous studies have provided evidence for a dissociation of GJIC
and the ability of connexins to inhibit cell proliferation and tumor
growth [21]. Mechanistic studies demonstrated that Cx43 over-
expression may inhibit cell proliferation via the inhibition of the ex-
pression of S phase kinase associated protein 2 (skp2), the protein
that promotes the ubiquitination of cyclin-dependent kinase inhibitor
p27kip [49]. With regard to primary bone tumors, a down-regulation
of cyclin D1 associated with a blockade of the cell cycle in G0/G1
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Supporting this observation, we demonstrated that Cx43 over-
expression in ES cells increases p27 levels with an associated marked
decrease of Rb phosphorylation, consistent with the observed block-
ade of the cell cycle in G0/G1 phase.
The presence of a “vicious cycle” established between tumor
proliferation and paratumor osteolysis plays a crucial role in the de-
velopment of primary bone tumors [53]. Cancer cells produce
soluble factors that activate directly or indirectly via osteoblasts,
osteoclast differentiation and maturation [54,55]. In turn, during
bone degradation, osteoclasts release tumor supportive growth fac-
tors stocked in the mineralized bone matrix [56]. Studies about the
cellular mechanisms underlying the rapid bone resorption in ES indi-
cate that ES cells activate osteoclast activity [4]. According with these
ﬁndings, we demonstrated that the increase in bone volume observed
after Cx43 overexpression in ES cells is due in large part to inhibition
of osteoclast activity rather than to stimulation of osteoblast activity.
The decrease of TRAP activity at the level of the growth plate, that is,
not in direct contact with the tumor, suggests that the overexpression
of Cx43 affects the ability of the tumor cells to produce a soluble
factor able to regulate osteoclast activity, such as RANKL or M-CSF.
This hypothesis is supported by previous reports demonstrating
that ES cells support osteoclast formation by a RANKL- and M-CSF-
dependent mechanism [4].
In conclusion, this report provides new insights regarding the role of
the tumor suppressor gene Cx43 in the ﬁrst stage of ES development,
speciﬁcally during the primary bone tumor growth. We speciﬁcally
demonstrated: 1) that Cx43 gene expression affects tumor growth by
a blockade of the cell cycle in G0/G1 phase consistent with an increase
of p27 level, and 2) that Cx43 gene expression plays a crucial role in
the “vicious cycle” established between tumor proliferation and
paratumor osteolysis by its ability to decrease osteoclast activity. The
role of Cx43 in the more late stage of ES development like metastatic
dissemination remains to be elucidated. Indeed, the role of connexins
in invasion andmetastasis seems to be evenmore complex, and several
reports suggest that connexins might facilitate invasion, intravasation,
extravasation and metastasis [57].
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